Mayne Pharma Group Ltd (MYX):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Mayne Pharma Group Ltd (MYX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3287
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストラリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Mayne Pharma Group Ltd (Mayne Pharma), formerly HalcyGen Pharmaceuticals Ltd, a subsidiary of Mayne Pharma Group Ltd, is a specialty pharmaceutical company that manufactures and markets branded and generic medicinal products. The company’s products comprise erymax capsules, kapanol capsules, doryx capsules, magnoplasm, astrix capsules and tablets, and lozanoc and itragerm capsules. It offers services such as analytical development, product development, contract manufacturing, logistics, and formulation development, others. Mayne Pharma offers its products in the dosage forms of tablets, capsules, powders, liquids, and creams. The company operates manufacturing facilities in Australia and the US. Mayne Pharma is headquartered in Adelaide, South Australia, Australia.

Mayne Pharma Group Ltd (MYX) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Mayne Pharma Acquires Efudex from Spear Pharma 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 14
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 15
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 17
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 18
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 19
Venture Financing 20
HedgePath Pharma Raises USD0.6 Million in Financing 20
Partnerships 21
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
Licensing Agreements 26
HedgePath Pharma Enters into Option Agreement with University of Connecticut 26
Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 27
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 28
HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 29
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 31
Equity Offering 32
HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 32
HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 33
Mayne Pharma Raises USD257 Million in Rights Offering of Shares 34
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 36
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 38
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 39
HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 40
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 41
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 42
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 43
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 44
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 46
Acquisition 47
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 47
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 48
Mayne Pharma Group Ltd – Key Competitors 50
Mayne Pharma Group Ltd – Key Employees 51
Mayne Pharma Group Ltd – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Recent Developments 54
Strategy And Business Planning 54
Apr 18, 2018: Mayne Pharma Opens New Solid Oral-dose Manufacturing Facility In US 54
Financial Announcements 55
Feb 23, 2018: Mayne Pharma Reports 2018 Half Year Performance 55
Aug 25, 2017: Mayne Pharma Reports FY17 Results 58
Feb 24, 2017: Mayne Pharma: 2017 Half Year Release 61
Corporate Communications 64
Jun 28, 2018: Mayne Pharma Names Patrick Blake As New Director 64
May 30, 2018: Mayne Pharma Announces New Board Director 65
Mar 09, 2017: Mayne Pharma appoints new Group CFO and Company Secretary 66
Jan 16, 2017: Mayne Pharma Announces Leadership Changes 67
Other Significant Developments 69
Aug 08, 2017: Mayne Pharma Market Update 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Mayne Pharma Acquires Efudex from Spear Pharma 13
Mayne Pharma Acquires Rights to Foam Assets from GlaxoSmithKline for USD50 Million 14
Mayne Pharma Acquires US Generic Products from Teva Pharma and Allergan for USD652 Million 15
Mayne Pharma to Acquire Doryx from Actavis for USD50 Million 17
Mayne Pharma Acquires Brands And Related Assets For Forest Labs For US$12 Million 18
Mayne Pharma Acquires Kapanol from GlaxoSmithKline for USD15 Million 19
HedgePath Pharma Raises USD0.6 Million in Financing 20
Mayne Pharma Enters into Distribution Agreement with IDT Australia 21
Mayne Pharma Enters Into Distribution Agreement With ISDIN For Subacap 22
Mayne Pharma Enters Into Distribution Agreement With Glenmark Pharma For Subacap 24
HedgePath Pharma Enters into Option Agreement with University of Connecticut 26
Mayne Pharma Enters into Licensing Agreement with Nestle Skin Health 27
HedgePath Pharma Enters into Sublicensing Agreement with Mayne Pharma 28
HedgePath Pharma Amends Licensing Agreement With Mayne Pharma 29
Mayne Pharma Group Enters Into Licensing Agreement With Intas Pharma For Injectable Products 31
HedgePath Pharma Raises USD1.6 Million in Second Tranche of Private Placement of Preferred Shares 32
HedgePath Pharma Raises USD2.4 Million in First Tranche of Private Placement of Preferred Shares 33
Mayne Pharma Raises USD257 Million in Rights Offering of Shares 34
Mayne Pharma to Raise USD212 Million in Private Placement of Shares 36
HedgePath Pharma Raises USD5.5 Million in Private Placement of Units 38
HedgePath Pharma Raises USD2.5 Million in Private Placement of Shares and Warrants 39
HedgePath Pharma Completes Private Placement of Shares for USD1.5 Million 40
Mayne Pharma Completes Private Placement Of Shares For US$16 Million 41
Mayne Pharma Group Completes Private Placement Of Shares For US$5 Million 42
Mayne Pharma Group Completes Private Placement Of Shares For US$0.14 Million 43
Mayne Pharma Group Completes Private Placement Of Shares For US$19 Million 44
Mayne Pharma Completes Final Tranche Of Private Placement Of Shares For US$4 Million 46
Mayne Pharma Acquires Libertas Pharma, Generic Pharma Company 47
Mayne Pharma Completes Acquisition Of Metrics For Up To US$120 Million 48
Mayne Pharma Group Ltd, Key Competitors 50
Mayne Pharma Group Ltd, Key Employees 51
Mayne Pharma Group Ltd, Other Locations 52
Mayne Pharma Group Ltd, Subsidiaries 52

List of Figures
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Mayne Pharma Group Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Mayne Pharma Group Ltd, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Mayne Pharma Group Ltd (MYX):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Airborne Systems, Ltd.:企業の戦略・SWOT・財務情報
    Airborne Systems, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Airborne Systems, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Parker Hannifin Corp (PH):医療機器:M&Aディール及び事業提携情報
    Summary Parker Hannifin Corp (Parker) is a manufacturer of motion and control technologies and systems. The company offers critical motion and control solutions, including fluid power systems, electromechanical controls and related components. Its products find use in various industries and applicat …
  • Medicure Inc (MPH):企業の財務・戦略的SWOT分析
    Summary Medicure Inc (Medicure) is a pharmaceutical company that strives to research, develop and commercialize therapeutics for cardiovascular diseases. The company offers products such as Aggrastat, a glycoprotein GP IIb/IIIa receptor antagonist indicated for the treatment of acute coronary syndro …
  • freenet AG:企業のM&A・事業提携・投資動向
    freenet AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's freenet AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • IAC/INTERACTIVECORP:企業の戦略・SWOT・財務分析
    IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report Summary IAC/INTERACTIVECORP - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tanfield Group PLC (TAN):企業の財務・戦略的SWOT分析
    Summary Tanfield Group plc (Tanfield Group) is an investment company that offers electrical investments. The company designs and produces electric commercial vehicles for short haul urban fleets. It also produces zero-emission vehicles that deliver better performance to traditional diesel trucks. Ta …
  • Valener Inc (VNR):石油・ガス:M&Aディール及び事業提携情報
    Summary Valener Inc (Valener) is an investment holding company that focuses on the energy sector. Through its investments in energy portfolio, the company offers storage, distribution, transportation and allied energy services. The company has interest in Gaz Metro and is its limited partner. Gaz Me …
  • Avacta Group Plc (AVCT):製薬・医療:M&Aディール及び事業提携情報
    Summary Avacta Group Plc (Avacta) is a developer therapeutic molecules used in a wide range of life sciences applications in research and diagnostics. The company offers products that include optim and sensipod. It also develops UCB celltech that is an analytical instrument. Avacta’s sensipod is an …
  • ACHEM Technology Corporation:企業の戦略・SWOT・財務情報
    ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report Summary ACHEM Technology Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Korres Natural Products SA:戦略・SWOT・企業財務分析
    Korres Natural Products SA - Strategy, SWOT and Corporate Finance Report Summary Korres Natural Products SA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • National Beverage Corp.:企業の戦略・SWOT・財務情報
    National Beverage Corp. - Strategy, SWOT and Corporate Finance Report Summary National Beverage Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Orion Diagnostica Oy-医療機器分野:企業M&A・提携分析
    Summary Orion Diagnostica Oy (Orion Diagnostica), a subsidiary of Orion Oyj, is a medical equipment company that develops, manufactures clinical diagnostic and hygiene monitoring tests. Its product portfolio provides diagnosis and treatment management kits, point of care systems, ready to use kits, …
  • TelaDoc Inc (TDOC)-医療機器分野:企業M&A・提携分析
    Summary TelaDoc Inc (Teladoc) is a provider of telehealth services. The company offers short term prescription for amoxicillin, azithromycin, bactrim DS, augmentin, cipro, tessalon perles, flonase nasal spray, pyridium, prednisone and diflucan. It provides telehealth services for cold and flu sympto …
  • PendoPharm Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary PendoPharm Inc (PendoPharm), a subsidiary of Pharmascience Inc, is a healthcare company that provides production and commercialization of a wide range of drugs. The company provides products such as spans prescription drugs, over-the-counter and behind-the-counter products, among others. Its …
  • De Beers Group Plc:企業の戦略・SWOT・財務情報
    De Beers Group Plc - Strategy, SWOT and Corporate Finance Report Summary De Beers Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Etiqa Life and General Assurance Philippines Inc:企業の戦略・SWOT・財務分析
    Etiqa Life and General Assurance Philippines Inc - Strategy, SWOT and Corporate Finance Report Summary Etiqa Life and General Assurance Philippines Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, …
  • The Procter & Gamble Co:企業のM&A・事業提携・投資動向
    The Procter & Gamble Co - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's The Procter & Gamble Co Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisition …
  • Arabtec Holding:企業の戦略・SWOT・財務情報
    Arabtec Holding - Strategy, SWOT and Corporate Finance Report Summary Arabtec Holding - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Verbund AG:発電所・企業SWOT分析
    Verbund AG - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (executi …
  • Korea Petrochemical Ind. Co Ltd (006650):企業の財務・戦略的SWOT分析
    Summary Korea Petrochemical Ind. Co Ltd (KPICL) is a chemical company that manufactures and markets petrochemical products. The company provides products such as olefins, aromatics, polypropylene, EO and EG, PP and HDPE. It provides olefins products such as ethylene, propylene, butene, butane, isobu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆